In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene fragment patents do not preclude subsequent patents for full gene, PTO tells NIH.

Executive Summary

GENE FRAGMENT PATENTS DO NOT PRECLUDE SUBSEQUENT FULL GENE PATENTS, PTO Commissioner Bruce Lehman said in a recent letter to the National Institutes of Health. "Patent claims, limited in scope to a specific novel and non-obvious EST [expressed sequence tag], generally should not preclude the future patenting of the corresponding, later discovered, full length gene of known function or of therapeutic technologies arising therefrom," Lehman wrote in the April 2 letter. The letter responds to two NIH letters sent to PTO in late March -- one from NIH Director Harold Varmus and the other from Office of Technology Transfer's Jack Spiegel.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel